Arterial Hypertension, a Frequent Comorbidity in Diabetes: the Perioperative Management

Hypertension
Hypertension

Abstract

Arterial hypertension and diabetes mellitus frequently coexist. Preexisting arterial hypertension is a main reason for postponing surgery in diabetic patients. Hypertension is a risk factor for cardiovascular complications during the perioperative period. The term peri-operative generally refers to the three phases of surgery: pre-operative, intra-operative, and post-operative.

Sympathetic activation during the induction of anesthesia can cause increases in blood pressure by 20 to 30 mm Hg and increases in heart rate by 15-20 beats per minute in patients with normal blood pressure values. These values are higher in patients with untreated hypertension. The effect of chronic hypertension on perioperative risk is determined primarily by the presence of target organ damage, coronary artery disease, stroke, heart failure and renal failure, all of which are known to affect perioperative morbidity and mortality. There are no randomized clinical trial data showing what the optimal blood pressure should be at the time of surgery. In patients with grade

1 or 2 hypertension, there is no evidence of benefit from delaying surgery to optimize therapy. In such cases, antihypertensive medications should be continued during the perioperative period.

Most antihypertensive drugs should be continued to the day of surgery and restart as soon as possible (when the patient will be able to swallow). Only agents that affect the renin-angiotensin- aldosterone system should be canceled (angiotensin-converting enzyme inhibitors and angiotensin receptor blockers). Regarding beta-blockers, the treatment should ideally be initiated between 30 days and at least 2 days before surgery, starting at a low dose, and should be continued post- operatively. The target is a resting heart rate 60-70 bpm and systolic blood pressure > 100 mm Hg.

 

Table of content

1. Introduction

2. Problems in the clinical practice

3. Management of perioperative hypertension

4. Conclusions

 

1. Introduction

Arterial hypertension is one of the most common cardiovascular diseases worldwide. Diabetic patients have an increased risk of arterial hypertension [1, 2]. Arterial hypertension is the most frequent preoperative abnormality in surgical patients [3, 4]. Preexisting arterial hypertension is a main reason for postponing surgery in diabetic patients. Moreover, hypertension is a risk factor for cardiovascular complications during the perioperative period [5]. The term perioperativegenerally refers to the three phases of surgery: pre-operative, intra-operative, and post-operative.

But how important is peri-operative hypertension? The effect of chronic hypertension on perioperative risk is determined primarily by the presence of target organ damage: coronary artery disease, stroke, heart failure, kidney failure, all of which affecting perioperative morbidity and mortality. Nowadays, it is not very clear if increased blood pressure values have an independent effect on morbimortality. Target organ damage associated with hypertension and total cardiovascular risk, rather than high blood pressure per se, seem to determine the perioperative risk. The perioperative outcomes depend also on associated hypertensive comorbidities: coronary artery disease, heart failure, left ventricle hypertrophy, kidney damage (serum creatinine > 2 mg/dL), and cerebrovascular disease [6, 7, 8].

From the pathophysiological point of view, there are many changes in the perioperative period which lead to increases of blood pressure values. The operative stress induces sympathetic activation, with increased cardiac output, sodium retention, vasoconstriction, increased heart rate.

The regulation of blood pressure depends on heart rate, left ventricle stroke volume and vascular resistance. Discontinuation of antihypertensive medication prior to or immediately after surgery is another reason for blood pressure increases during the perioperative period. The sympathetic activation in the perioperative period is even more pronounced in untreated hypertensive patients. Acute hypertension increases the risk of bleeding at the surgical site or intracranial and the risk of myocardial ischemia.

75% of patients in the perioperative period have increased blood pressure for 2-6 hours [9]. The perioperative hypertension is common with coronary artery by-pass graft (30-80%) [9]. The incidence of perioperative hypertension is increasing, due to aging population, increased use of cardiovascular procedures, decreased use of opioid anesthesia and postoperative sedation.

 

2. Problems in the clinical practice

In the clinical practice, there are some controversies regarding the management of hypertensive patients [10, 11]. These controversies are related to antihypertensive drugs interactions with anesthesia, the influence of antihypertensive medication on the peri-operative outcome, management of surgical patients with isolated systolic hypertension or white ‘coat hypertension, indications for postponing or even cancellation of surgery in hypertensive patients [12].

Perioperative hypertension occurs during induction of anesthesia, hypothermia, hypoxia, intraoperatively due to pain-induced sympathetic stimulation, intravascular volume overload in the first 24-48 hours postoperatively, as fluid is mobilized from extravascular space. During the induction of anesthesia, sympathetic activation may induce a blood pressure increase by 20-30 mm Hg and the heart rate increase by 15-20 bpm in normotensive individuals; these responses may be more important in patients with untreated hypertension. As anesthesia progresses, hypertensive patients are more likely to present intraoperative blood pressure lability, with an increased risk of myocardial ischemia. After surgery, pain, agitation, hypoxemia, hypervolemia, hypercapnia may induce postoperative hypertension.

When assessing patients with arterial hypertension prior to surgery, there is a number of questions that must be answered: Is the patient known with arterial hypertension or is a newly diagnosed hypertension? Is the patient under treatment with antihypertensive drugs? Is it a primary or a secondary hypertension? Does the patient have a treatable cause of hypertension? Does the patient have white-coat hypertension?Is there a need to modify the drugs doses perioperatively? Should we postpone the operation in order to control the blood pressure? What additional tests are needed? Which is the appropriate pharmacotherapy before, during and after the operation?

Therefore, in some cases, the referring physician should be contacted in order to obtain a more accurate medical history and blood pressure values than the ones measured during the current hospital admission.

The preoperative evaluation of a hypertensive patient should identify undiagnosed or uncontrolled hypertensives and estimate the true level of the blood pressure values, in order to reduce the operative risk in the short-term period and the adverse long-term effects. Perioperative hypertension usually lasts 2-6 hours and requires rapid intervention, to avoid mortality and unplanned critical care admissions.

For a correct diagnosis, the measurement of the blood pressure should strictly adhere to the recommendations of the guidelines: the patient must sit quietly, he should not be engaged in any conversation, the arm should be at the heart level, an appropriate size cuff should be used. If the blood pressure is found increased, a second measurement should be done, with an interval of at least 1 minute between readings. Postoperatively, the blood pressure must be measured every 5-

15 min during the first hour, then every 30 min until 3 hours postoperative. If the diagnosis of

arterial hypertension is established, the assessment of the organ damage is important, because heart failure, renal impairment, coronary artery disease or cerebrovascular disease may increase the perioperative risk [13].

A blood pressure higher than 180/110 mm Hg defines a hypertensive crisis, the patient being at risk for end-organ damage. The hypertensive urgency is the severe asymptomatic hypertension, whereas hypertensive emergency defines the presence of end-organ damage. The signs and symptoms of end-organ damage in a hypertensive emergency are chest pain, arrhythmias, dyspnea, orthopnea, peripheral edema, headache, vomiting, seizure, hematuria, proteinuria, weakness, numbness, blurred vision, retinal hemorrhage, severe anxiety.

 

3. Management of perioperative hypertension

Common reasons for delayed surgery in patients with hypertension are: poorly controlled arterial hypertension grade 3 according to the European Society of Cardiology (systolic blood pressure ≥ 180 mm Hg and/or diastolic blood pressure ≥ 110 mm Hg), identifying end-organ damage that has not been previously been evaluated or treated, suspicion of secondary hypertension without properly documented etiology [14]. There are no randomized clinical trial data showing what the optimal blood pressure should be at the time of surgery. The 2014 European Society of Cardiology Guidelines on non-cardiac surgery mention that in patients with grade 1 or 2 hypertension (systolic blood pressure < 180 mm Hg, diastolic blood pressure < 110 mm Hg), there is no evidence of benefit from delaying surgery to optimize therapy [15]. In such cases, antihypertensive medications should be continued during the perioperative period [16]. Most antihypertensive drugs should be continued to the day of surgery and restart as soon as possible (when the patient will be able to swallow). Only renin-angiotensin system inhibitors should be stopped the morning of surgery [17]. Diuretics should be maintained until surgery (they may be stopped the day of surgery in case of hypovolemia).

Regarding angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, the European Society of Cardiology Guidelines recommend continuation of these drugs, under close monitoring, during non-cardiac surgery in stable patients with heart failure and left ventricle systolic dysfunction [14]. Treatment with beta-blockers should ideally be initiated between 30 days and (at least) 2 days before surgery, starting at a low dose, and should be continued post- operatively [14]. The target is a resting heart rate of 60-70 bpm, and a systolic blood pressure >100 mm Hg [14]. In patients under treatment with beta-blockers, the continuation of treatment is recommended. Preoperative initiation of beta-blockers may be considered in patients with coronary heart disease or myocardial ischemia. According to the results of POISE trial, perioperative use of beta-blockers may benefit only patients at highest risk and may harm other patients: in patients with Lee index > 3 there is a significant decrease in mortality, with Lee index 1 or 2 there is no significant difference and if Lee index is 0 there is an increase in mortality [18].

Preoperative beta-blockers withdrawal leads to an increase in mortality [18].

Among perioperative complications, acute postoperative hypertension is the most frequent one. The acute postoperative hypertension manifests in the first 20 minutes of the postoperative period and lasts an average of 3 hours. If it is left untreated, the acute postoperative hypertension is a major risk factor for bleedings, stroke, myocardial ischemia, arrhythmias, heart failure with pulmonary congestive edema, other vascular complications [19].

Esmolol and labetalol are the beta-blockers of choice for the treatment of acute postoperative hypertension [20]. Esmolol has the onset of action in 1-2 min and the half-life of 9 min. It is indicated in intraoperative and postoperative tachycardia and/or hypertension, and in supraventricular tachycardia [20]. It is contraindicated in sinus bradycardia, 2nd or 3rd-degree heart blocks, cardiogenic shock or overt heart failure. Labetalol is a combined non-selective beta- blocker and alpha1-blocker, but the beta-blockade is 7 times higher than alpha-blockade. It is not associated with decreased cardiac output seen with other beta-blockers. The onset of action is in 5-15 min per bolus and the half-life is 5 1/2 hours. Labetalol is indicated to control the blood pressure in severe hypertension [20].

Nitroprusside is a vasodilator for both arteries and veins, with the onset of action less than 1 min and a half-life of 3-4 min. Treatment with nitroprusside requires careful blood pressure monitoring with intra-arterial line and frequent dosage adjustments [20]. The initial dose is 0.5 mcg/Kg/minute. Nitroglycerin is a vasodilator with a rapid onset of action and it is useful in patients with heart failure, cardiac ischemia. The initial dose is 5 mcg/min and the onset of action is between 2-5 minutes [20]. Hydralazine may be used for acute postoperative hypertension, 3-20 mg initially, with an onset of action between 5-15 minutes and a duration of action of 6-12 hours [20]. Enalaprilat is used in an initial dose of 0.625-1.25 mg, with an onset of action of 15 minutes and a duration of action of 6 hours; it is indicated when oral therapy is not practical [20].

Fenoldopam is a dopamine D1-receptor agonist with an onset of action < 5 min and a half-life of 5 min [20]. It is indicated for the short-term management of severe arterial hypertension and it has no contraindications, but in some patients may cause allergic reactions. Other antihypertensive agents which may be used for the treatment of acute postoperative hypertension are nicardipine, clevidipine, clonidine, urapidil. Nicardipine is a very selective dilator, used in doses of 1-5 mg/hour for 12 hours maximum [20].

If the patient has severe hypertension, with values higher than 180/110 mm Hg, the physician should carefully search for symptoms and signs of end-organ damage: stroke, encephalopathy, myocardial ischemia, heart failure, renal or visual impairment. Antihypertensive treatment should be administered immediately, with the goal to decrease the blood pressure with no more than 25% during the first hour, in order to avoid organ perfusion deficits.

 

4. Conclusions

Perioperative hypertension is frequently encountered in the surgical wards and requires pharmacological treatment.

There are no specific guidelines regarding the management of perioperative hypertension. The treatment must be individualized according to the values of the blood pressure, end-organ damage, and associated comorbidities [21-24].

There are no significant differences in outcomes of surgical patients, normotensive, and those hypertensives, with a blood pressure less than 180/110 mm Hg. Patients referred to surgery with blood pressure values higher than 180/110 mm Hg should be carefully examined and monitored for signs of end-organ damage. If the patient has other cardiovascular risk factors and a nonemergent high-risk surgery is scheduled, surgery may be delayed until a better control of the blood pressure values with oral medication [25, 26]. If severe hypertension with signs of end- organ damage is present (hypertensive emergency), and there is no surgical emergency, then surgery must be rescheduled and intravenous antihypertensive treatment should be administered immediately.

There is no perfect antihypertensive treatment for hypertensive emergencies. The choice of drug depends mainly on the associated comorbidities [28, 29]. Patients should be carefully monitored during administration of antihypertensive treatment, in order to avoid signs of organs hypoperfusion.

 

Contributo selezionato da Filodiritto tra quelli pubblicati nei Proceedings “35th Balkan Medical Week - 2018”

Per acquistare i Proceedings clicca qui:

https://www.filodiritto.com/proceedings

 

Contribution selected by Filodiritto among those published in the Proceedings “35th Balkan Medical Week - 2018”

To buy the Proceedings click here:

https://www.filodiritto.com/proceedings

1. Diaconu, C.; et al., (2016). Type 2 diabetes: a driver for chronic heart failure. Proceedings of the 2nd International Conference on Interdisciplinary Management of Diabetes Mellitus and its Complications – Diabetes mellitus as cardiovascular disease, INTERDIAB 2016, Serafinceanu, C.; Negoiţă, O.; Elian, V. (Ed.), 201-210, ISSN 2393-3488, Bucharest, March 2016, Editura Niculescu, Bucharest.

2Iancu, M.A.; et al., (2016). An analysis of hypertensive male patients addressed to a primary practice. J Hypertens 34, e-Suppl 1, e323.

3. Niculae, A.; et al., (2016). Renal artery bilateral arteriosclerosis cause of resistant hypertension in hemodialysed patients. Rom J Morphol Embryol. 57(2), pp. 591-4.

4Checheriţă, I.A.; et al., (2013). Calcific uremic arteriolopathy in hemodialyzed patients. Chirurgia (Bucur)108(5), pp. 736-40.

5Barbu, C.G.; et al., (2017). Cardiovascular risk assessment in osteoporotic patients using osteoprotegerin as a reliable predictive biochemical marker. Molecular Medicine Reports, 16(5), pp. 6059-6067.

6. Diaconu, C.; et al., (2016). A comparative analysis of the hypertension treatment depending on comorbidities: insights from clinical practice. J Hypertens 34, e-Suppl 1, e320.

7. Diaconu, C.; et al., (2016). An age-related comparison between comorbidities and treatment of hypertensive patients. J Hypertens 34, e-Suppl 1, e321.

8. Diaconu C. (2017). Midaortic syndrome in a young man. Cor et Vasa 59, e171-e173.

9Colombo, J.A.; et al., (1999). Perioperative hypertension and outcome. Anesthesiology Clinics of North America, 17(3), pp. 581-591.

10. Drăgoi, C.M.; et al., (2016). Characteristics of glucose homeostasis and lipidic profile in a hamster metabolic syndrome model, after the co-administration of melatonin and irbesartan in a multiparticulate pharmaceutical formulation. Proceedings of the 2nd International Conference on Interdisciplinary Management of Diabetes Mellitus and its Complications – Diabetes mellitus as cardiovascular disease, INTERDIAB 2016, Serafinceanu, C.; Negoiţă, O.; Elian, V. (Ed.), 221-229, ISSN 2393-3488, Bucharest, March 2016, EditurNiculescu, Bucharest.

11Prodan (Pura), G.; et al., (2017). The impact of urapidil use in hypertension prehospital emergency intervention. Farmacia, 65(6), pp. 896-899.

12. Mohamad, M.A.; et al., (2014). The dynamics of adiponectin and leptin on metabolic syndrome patients and age matched healthy subjects. Farmacia, 62(3), pp. 532-545.

13Confederat, L.; et al., (2016). Side effects induced by hypoglycaemic sulfonylureas to diabetic patients - a retrospective study. Farmacia, 64(5), pp. 674-679.

14. Mancia, G.; et al., (2013). 2013 ESH/ESC Guidelines for the management of arterial hypertension. EuropeaHeart Journal, 34, pp. 2159-2219.

15. Kristensen, S.D.; et al., (2014). 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management. European Heart Journal, 35, pp. 2383-2431.

16Buda, V.; et al., (2016). The influence of perindopril on ptx3 plasma levels in hypertensive patients with endothelial dysfunction. Farmacia, 64(3), pp. 382-389.

17. Drăgoi, C.M.; et al., (2016). Characteristics of glucose homeostasis and lipidic profile in a hamster metabolic syndrome model, after the co-administration of melatonin and irbesartan in a multiparticulate pharmaceutical formulation. Proceedings of the 2nd International Conference on Interdisciplinary Management of Diabetes Mellitus and its Complications – Diabetes mellitus as cardiovascular disease, INTERDIAB 2016, Serafinceanu, C.; Negoiţă, O.; Elian, V. (Ed.), 221-229, ISSN 2393-3488, Bucharest, March 2016, Editura Niculescu, Bucharest.

18. Devereaux, P.J.; et al., (2008). Efects of extended-release metoprolol succinate in patients undergoing non- cadiac surgery (POISE trial): a randomised controlled trial. The Lancet, 371, pp. 1839-47.

19. Diaconu, C. (2017). Treatment of diabetes in patients with heart failure. Proceedings of the 3rd International Conference on Interdisciplinary Management of Diabetes Mellitus and its Complications – Diabetes mellitus as cardiovascular disease, INTERDIAB 2017, Serafinceanu, C.; Negoiţă, O.; Elian, V. (Ed.), 170-177, ISS2393-3488, Bucharest, March 2017, Editura Niculescu, Bucharest.

20. Varon, J.; Marik, P.E. (2000). The diagnosis and management of hypertensive crises. Chest, 118(1), pp. 214227.

21. Vlăsceanu, A.M.; et al., (2015). Quantitative relationships of urinary cotinine levels in smoking diabetic patients. Farmacia, 63(3), pp. 349-356.

22. Gruia, V.; et al., (2009). The HPLC plasmatic profile of some fat-soluble antioxidant micronutrients (all-trans-retinol, α-tocopherol, coenzime Q10) in diabetic and dyslipidemic patients. Farmacia, 57(5), pp. 630-638.

23Plouin, P. (2017). Pourqoui rechercher une hypertension secondaire? Arch Balk Med Union, 52(2), pp. 133-134.

24Bălăceanu, A. et al., (2017). Hypertension in a young male patient: chronic stress as the only trigger. Arch Balk Med Union, 52(2), pp. 215-220.

25. Dediu, G.; et al., (2017). The effect of continuous positive airway pressure on blood pressure in patients with obstructive sleep apnea syndrome. Arch Balk Med Union, 52(4), pp. 430-433.

26Popa, E., Traian, M.G., Bacusca, A.I., Slanina, A.M., Boanca, M., Macovei, I., Popa, A., Coman, A.E. (2018). Évaluation de la tension arrielle et de la pression du pouls dans le syndrome métabolique. Arch Balk Med Union 53(3), pp. 393-400.

27. Diaconu, C.C., Dragoi, C.M., Bratu, O.G., Neagu, T.P., Pantea Stoian, A., Cobelschi, P.C., Nicolae, A.C., Iancu, M.A., Hainarosie, R., Stanescu, A.M.A., Socea, B. (2018). New approaches and perspectives for the pharmacological treatment of arterial hypertension. Farmacia 66(3), pp. 408-415.

28. Papaioannou, T.G., Gialafos, E., Vavuranakis, M., Vrachatis, D., Soulis, D., Siasos, G., Kyrlagkitsis, S., Stefanadis, C., Tousoulis, D. (2018). A novel geometrical analysis of the arterial pulse based on the golden ratio φ (phi): association with heart rate variability. Arch Balk Med Union 53(2), pp.179-188.

29. Diaconu, C.C., Dediu, G.N., Iancu, M.A. (2018). Drug-induced arterial hypertension, a frequently ignored cause of secondary hypertension: a review. Acta Cardiologica. DOI 10.1080/00015385.2017.1421445.